Sunday, November 22, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > News > AstraZeneca vaccine

AstraZeneca vaccine

in News
Share on LinkedinShare on WhatsApp

AstraZeneca’s vaccine could be ready for large-scale trials by year-end, says CEO Pascal Soriot.

One day after Kate Bingham, chair of the U.K. Vaccine Taskforce, said only 4 million doses of the shot would be available by the end of the year, AstraZeneca’s Chief Executive Officer Pascal Soriot said the U.K. drugmaker is poised to unveil vaccine test results by year-end even after trials were slightly delayed over the summer as infection rates slowed in the northern hemisphere, Bloomberg reports.

“At the end of the day, we don’t yet know if the vaccine works,” Soriot said in a Bloomberg Television interview, adding that many questions remain, such as whether it will show results for everyone and for how long. “We would hope that large-scale vaccinations would be possible starting in January next year — possibly even December.”

AstraZeneca said it’s confident it can begin supplying hundreds of millions of doses on a “rolling basis” once a shot is cleared. According to Soriot, a recent resurgence has allowed scientists to gather the clinical data they need. Astra and the University of Oxford are keeping the vaccine in a frozen bulk state to preserve its shelf life while they await final test results.

Pfizer, which is developing its vaccine with Germany’s BioNTech SE, has said it may release initial late-stage trial data this month. The company is also waiting to hit a safety milestone, two months of data on half of participants, which it expects by the third week of November.

Tags: AstraZenecaCEOCEO NorthamCOVIDPascal SoriotVaccine

Related Posts

Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment
News

Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment

Bending Spoons acquires Mailchimp in $3.68 billion deal
News

Bending Spoons acquires Mailchimp in $3.68 billion deal

PayPal appoints HP’s Enrique Lores as CEO
News

PayPal names Claire Bramley as new CFO

Google selects Bezos’ Blue Origin for AI space project
News

Google selects Bezos’ Blue Origin for AI space project

Anthropic sets $1 trillion IPO valuation target
News

Anthropic raises more than $81 billion in record IPO

Walmart beats predictions in latest quarter
News

Walmart raises outlook, anticipating a busy holiday season

U.S. officials order Nvidia to stop sales of AI chips to China
News

Nvidia shares rally following earnings beat

Target aims for non-alcoholic cocktail market ahead of the holiday season
News

Target reports its strongest sales growth in five years

Huang joins top CEOs on Trump’s China trip
News

Trump arrives in China for historic Xi, Putin meeting

The IMF-World Bank meetings commence in Washington
News

IMF chief gives stark warning on global economy 

No Result
View All Result

Recent Posts

  • Why are we so obsessed with the ’90s?
  • U.S. Loses Measles-Free Status After 26 Years
  • Plane clapping – joyful or deeply cringe?
  • The 4 themes shaping new manufacturing
  • Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.